Dexlansoprazole PCD Pharma Franchise Company
Cafoli Lifecare offers a Dexlansoprazole range of 3 capsule formulations, manufactured in WHO-GMP certified facilities. Distributors serving gastroenterology and general-practice prescribers can secure district-wise monopoly franchise rights for this modern proton-pump inhibitor with full promotional support.
What is Dexlansoprazole?
Dexlansoprazole is a proton-pump inhibitor (PPI) and the active R-enantiomer of lansoprazole. Its dual delayed-release formulation gives two separate drug-release phases for prolonged acid suppression and flexible, food-independent once-daily dosing. Reference: PubChem - Dexlansoprazole.
Available Forms
The Cafoli Dexlansoprazole portfolio is offered as oral dual-release Capsules in the commonly prescribed strengths (30mg, 60mg). Contact us for current pack presentations and combinations.
Therapeutic Applications
Dexlansoprazole is prescribed for gastro-oesophageal reflux disease (GERD), healing and maintenance of erosive oesophagitis, and relief of heartburn and acid-related dyspepsia. Prescribers include gastroenterologists, physicians and general practitioners.
Why Dexlansoprazole is a High-Potential Molecule for Distributors
Acidity and reflux are among the most common complaints in India, and PPIs are a huge, everyday category. Dexlansoprazole is a premium, differentiated PPI whose dual-release, take-anytime dosing appeals to patients poorly controlled on older agents, letting distributors offer a higher-value option in a very high-volume segment.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Dexlansoprazole
- MedlinePlus: Dexlansoprazole
- PubMed: dexlansoprazole in GERD
Our formulations of Dexlansoprazole find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: